PHI with Epidermolysis bullosa simplex
How does this condition affect your private health insurance?
Epidermolysis bullosa simplex (EBS) is a group of genetic skin disorders characterized by extreme skin fragility, leading to recurrent blistering upon minor trauma or friction. Caused by mutations primarily in KRT5 or KRT14 genes, it affects the keratin proteins in the basal layer of the epidermis. Blisters typically heal without scarring but can be painful and prone to infection. The severity varies significantly, from localized blistering on hands and feet to more generalized forms impacting larger body areas. EBS is a lifelong condition, primarily managed through symptom control and protective measures.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Lifelong, with episodes of blistering lasting days to weeks depending on trauma and healing.
Duration of Illness (Lifetime)
Chronic, lifelong disease.
Cost of Treatment (Initial)
Moderate to high, involving diagnostics, specialist consultations, initial wound care, and protective measures.
Cost of Treatment (Lifetime)
High, including ongoing wound care supplies, dermatology visits, pain management, infection treatment, and adaptive lifestyle adjustments.
Mortality Rate
Very low; generally not life-threatening, but severe forms can impact quality of life significantly.
Risk of Secondary Damages
High; includes chronic pain, infections, heat intolerance, limited mobility, psychological distress, and potential nutritional deficiencies if oral blistering occurs.
Probability of Full Recovery
Extremely low; currently no cure, management focuses on symptom control and complication prevention.
Underlying Disease Risk
Low probability of other underlying systemic diseases directly caused by EBS; however, patients are more susceptible to skin infections and potential nutritional issues.